Table 3.
Characteristics of Australians resident in aged care, aged 65+ years overall and according to vaccine doses received at 1 January 2022.
| Mean age (SD) | Unvaccinated (N = 10,927) |
1 dose (N = 5004) |
2 doses (N = 72,740) |
3 doses (N = 88,857) |
4 doses (N = 102) |
Total (N = 177,630) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.3 (8.5) |
84.9 (8.2) |
85.2 (7.8) |
86.1 (7.9) |
85.0 (8.1) |
85.7 (7.9) |
|||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |
| Age group (years) | ||||||||||||
| 65–79 | 2749 | 25.2% | 1310 | 26.2% | 17,042 | 23.4% | 18,224 | 20.5% | 28 | 27.5% | 39,353 | 22.2% |
| 80+ | 8178 | 74.8% | 3694 | 73.8% | 55,698 | 76.6% | 70,633 | 79.5% | 74 | 72.5% | 138,277 | 77.8% |
| Sexa | ||||||||||||
| Men | 3635 | 33.3% | 1840 | 36.8% | 25,709 | 35.3% | 28,347 | 31.9% | 51 | 50.0% | 59,582 | 33.5% |
| Women | 7285 | 66.7% | 3160 | 63.1% | 47,002 | 64.6% | 60,465 | 68.0% | 54 | 52.9% | 117,966 | 66.4% |
| State of residence | ||||||||||||
| New South Wales | 2758 | 25.2% | 1372 | 27.4% | 22,367 | 30.7% | 32,013 | 36.0% | 46 | 45.1% | 58,556 | 33.0% |
| Victoria | 2046 | 18.7% | 957 | 19.1% | 17,093 | 23.5% | 25,238 | 28.4% | 25 | 24.5% | 45,359 | 25.5% |
| Queensland | 3025 | 27.7% | 1276 | 25.5% | 15,201 | 20.9% | 15,517 | 17.5% | 10 | 9.8% | 35,029 | 19.7% |
| Others | 3102 | 28.4% | 1401 | 28.0% | 18,081 | 24.9% | 16,088 | 18.1% | 26 | 25.5% | 38,698 | 21.8% |
| No. of comorbiditiesb | ||||||||||||
| 0 | 3222 | 29.5% | 1051 | 21.0% | 12,584 | 17.3% | 15,800 | 17.8% | 21 | 20.6% | 32,678 | 18.4% |
| 1 | 2881 | 26.4% | 1257 | 25.1% | 17,852 | 24.5% | 22,742 | 25.6% | 22 | 21.6% | 44,754 | 25.2% |
| 2 | 2497 | 22.9% | 1206 | 24.1% | 19,179 | 26.4% | 23,819 | 26.8% | 33 | 32.4% | 46,734 | 26.3% |
| 3+ | 2325 | 21.3% | 1492 | 29.8% | 23,129 | 31.8% | 26,495 | 29.8% | 33 | 32.4% | 53,474 | 30.1% |
| No. of GP visits in year prior | ||||||||||||
| 0–10 | 2561 | 23.4% | 1004 | 20.1% | 12,320 | 16.9% | 16,745 | 18.8% | 14 | 13.7% | 32,644 | 18.4% |
| 11–20 | 3035 | 27.8% | 1375 | 27.5% | 20,587 | 28.3% | 22,634 | 25.5% | 30 | 29.4% | 47,661 | 26.8% |
| 21–30 | 2376 | 21.7% | 1153 | 23.0% | 17,337 | 23.8% | 20,299 | 22.8% | 18 | 17.6% | 41,183 | 23.2% |
| 31–40 | 1397 | 12.8% | 683 | 13.6% | 10,778 | 14.8% | 12,763 | 14.4% | 14 | 13.7% | 25,635 | 14.4% |
| 41–50 | 836 | 7.7% | 446 | 8.9% | 6130 | 8.4% | 8181 | 9.2% | 13 | 12.7% | 15,606 | 8.8% |
| 51–70 | 576 | 5.3% | 281 | 5.6% | 4425 | 6.1% | 6530 | 7.3% | 6 | 5.9% | 11,818 | 6.7% |
| 71+ | 143 | 1.3% | 65 | 1.3% | 1163 | 1.6% | 1701 | 1.9% | 3 | 2.9% | 3075 | 1.7% |
| Influenza vaccine in 2021 | 3978 | 36.4% | 2559 | 51.1% | 45,796 | 63.0% | 54,650 | 61.50% | 54 | 52.9% | 107,037 | 60.3% |
| COVID-19 vaccine primary doses branda | ||||||||||||
| Pfizer (BNT162b2) | 3486 | 69.7% | 49,490 | 68.0% | 84,222 | 94.8% | 93 | 91.2% | 137,291 | 77.3% | ||
| Astra Zeneca (ChAdOx1) | 1412 | 28.2% | 22,924 | 31.5% | 4627 | 5.2% | 11 | 10.8% | 28,974 | 16.3% | ||
| Moderna (mRNA-1273) | 90 | 1.8% | 260 | 0.5% | 0 | 0.0% | 0 | 0.0% | 350 | 0.2% | ||
| Mean number of weeks since receipt of most recent dose (SD) | 16.7 (13.4) | 23.7 (10.4) | 4.2 (2.0) | 4.4 (3.6) | ||||||||
a
For COVID-19 vaccine primary doses the % is of all those receiving that dose but for the overall population it includes the unvaccinated.
b
See methods for how co-morbid conditions were determined. All numbers were perturbed to maintain confidentiality. See methods for details.